The geoepidemiology of the antiphospholipid antibody syndrome

Autoimmunity Reviews

Volumn 9, Issue 5, 2010, Pages

  Biggioggero, Martina ^a,b   Meroni, Pier Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Antiphospholipid antibody; Antiphospholipid syndrome; Epidemiology

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HUMAN; KIDNEY DISEASE; LIVEDO RETICULARIS; NEUROLOGIC DISEASE; PREGNANCY DISORDER; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VACCINATION; VALVULAR HEART DISEASE; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CHILD; FEMALE; HUMANS; PREGNANCY; SYNDROME;

EID: 77649232595     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.11.013     Document Type: Review

References (57)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
2. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun Rev 6 (2006) 76-80
3. Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk?. Curr Rheumatol Rep 3 (2001) 271-276
4. Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C., Rodriguez-Martorell J., and Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31 (2004) 1560-1567
5. Cervera R. Lessons from the "Euro-phospholipid" project. Autoimmun Rev 7 (2008) 174-178
6. Meroni P.L., Peyvandi F., Foco L., Bernardinelli L., Fetiveau R., Mannucci P.M., et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5 (2007) 2421-2428
7. Mchrani T., and Petri M. Epidemiology of the antiphospholipid syndrome. In: Asherson R.A. (Ed). Hanbook of systemic autoimmune diseases vol. 10 (2009), Elsevier, Amsterdam 13-34
8. APASS (The Antiphospholipid Antibodies in Stroke Study). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 48 (1997) 91-94
9. Galli M., Luciani D., Bertolini G., and Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003) 1827-1832
10. Galli M., Luciani D., Bertolini G., and Barbui T. Antibeta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102 (2003) 2717-2723
11. Cervera R., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Kiss E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 68 (2009) 1428-1432
12. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117 (1992) 997-1002
13. Schulman S., Svenungsson E., Granqvist S., and The Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104 (1998) 332-338
14. Zoghlami-Rintelen C., Vormittag R., Sailer T., Lehr S., Quehenberger P., Rumpold H., et al. The presence of IgG antibodies against anti-B2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 3 (2005) 1160-1165
15. Opatrny L., David M., Kahn S.R., Shrier I., and Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 33 (2006) 2214-2221
16. Vora S., Shetty S., and Ghosh K. Thrombophilic dimension of recurrent fetal loss in Indian patients. Blood Coagul Fibrinolysis 19 (2008) 581-584
17. Lee R.M., Brown M.A., Branch W., Ward K., and Silver R.M. Anticardiolipin and anti-B2-glycoprotein I antibodies in preeclampsia. Obstet Gynecol 102 (2003) 294-300
18. Nodler J., Moolamalla S.R., Ledger E.M., Nuwayhid B.S., and Mulla Z.D. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 16 (2009) 9-11
19. Faden D., Tincani A., Tanzi P., Spatola L., Lojacono A., Tarantini M., et al. Anti-beta 2 glycoprotein I antibodies in general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 73 (1997) 37-42
20. Vianna J.L., Khamashta M.A., Ordi-Ros J., Font J., Cervera R., Lopez-Soto A., et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 96 (1994) 3-9
21. Alarcón-Segovia D., Pérez-Ruiz A., and Villa A.R. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 15 (2000) 157-161
22. Laskin C.A., Clark C.A., and Spitzer K.A. Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts?. Rheum Dis Clin North Am 31 (2005) 255-272
23. Danowski A., de Azevedo M.N., de Souza Papi J.A., and Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36 (2009) 1195-1199
24. Gomez-Pacheco L., Villa A.R., Drenkard C., Cabiedes J., Cabral A.R., and Alarcon-Segovia D. Serum antibeta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 106 (1999) 417-423
25. McClain M.T., Arbuckle M.R., Heinlen L.D., Dennis G.J., Roebuck J., Rubertone M.V., et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of Systemic Lupus Erythematosus. Arthritis Rheum 50 (2004) 1226-1232
26. Wahl D.G., Guillemin F., De Maistre E., Perret-Guillaume C., Lecompte T., and Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 6 (1997) 467-473
27. Somers E., Magder L.S., and Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 29 (2002) 2531-2536
28. Danowski A., Kickler T.S., and Petri M. Anti-B2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 33 (2006) 1775-1779
29. Clowse M.E., Magder L., Witter F.R., and Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 107 (2006) 293-299
30. Meroni P.L., Mari D., Monti D., Coppola R., Capri M., Salvioli S., et al. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp Gerontol 39 (2004) 1459-1465
31. Sène D., Piette J.C., and Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infection. Autoimmun Rev 7 (2008) 272-277
32. Shoenfeld Y., Meroni P.L., and Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 67 (2008) 438-442
33. Ramos-Casals M., Brito-Zerón P., Soto M.J., Cuadrado M.J., and Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22 (2008) 847-861
34. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8 (2009) 274-280
35. Tincani A., Taraborelli M., and Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev (2009) Apr 19. Electronic publication ahead of print
36. Cabiedes J., Trejo-Hernandez J., and Loredo-Abdala A. Anti-cardiolipin, anticardiolipin plus bovine, or human b2glycoprotein-I and anti-human b2glycoprotein-I antibodies in a healthy infant population. Arch Med Res 33 (2002) 175-179
37. Avčin T., Cimaz R., Silverman E.D., et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 122 (2008) e1100-e1107
38. Uthman I., and Khamashta M. Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis 64 (2005) 1671-1676
39. Sebastiani D., Minisola G., and Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2 (2003) 387-394
40. Yin H., Borghi M.O., Delgado-Vega A.M., Tincani A., Meroni P.L., and Alarcón-Riquelme M.E. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 60 (2009) 2468-2471
41. Tuthill J.I., and Khamashta M.A. Management of antiphospholipid syndrome. J Autoimmun 33 (2009) 92-98
42. Cervera R., Bucciarelli S., Plasin M.A., Gómez-Puerta J.A., Plaza J., Pons-Estel G., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 32 (2009) 240-245
43. Ortega-Hernandez O.D., Agmon-Levin N., Blank M., Asherson R.A., and Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 32 (2009) 1-6
44. Nacinovich R., Galli J., Bomba M., Filippini E., Parrinello G., Nuzzo M., et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum 59 (2008) 345-351
45. Sakai Y., Atsumi T., Ieko M., Amengual O., Furukawa S., Furusaki A., et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthriti Rheum 60 (2009) 2457-2467
46. Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Autoimmun Rev 9 (2009) 90-92
47. Bu C., Gao L., Xie W., et al. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 60 (2009) 559-568
48. Sitia S., Atzeni F., Sarzi-Puttini P., et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 8 (2009) 281-286
49. Rahgozar S., Giannakopoulos B., Yan X., et al. Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies. Arthritis Rheum 58 (2008) 1146-1155
50. Meroni P.L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 30 (2008) 99-103
51. Shoenfeld Y., Twig G., Katz U., and Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 30 (2008) 74-83
52. Sorice M., Longo A., Capozzi A., Garofalo T., Misasi R., Alessandri C., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 56 (2007) 2687-2697
53. Lin W.S., Chen P.C., Yang C.D., Cho E., Hahn B.H., Grossman J., et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 56 (2007) 1638-1647
54. Rahgozar S., Yang Q., Giannakopoulos B., Yan X., Miyakis S., and Krilis S.A. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum 56 (2007) 605-613
55. Shi T., Giannakopoulos B., Yan X., Yu P., Berndt M.C., Andrews R.K., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 54 (2006) 2558-2567
56. Lopez-Pedrerra C., Buendia P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbarroja N., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathways, and of the MEK-1/ERK pathway. Arthritis Rheum 54 (2006) 301-311
57. Mok M.Y., Chan E.Y., Fong D.Y., Leung K.F., Wong W.S., and Lau C.S. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 32 (2005) 622-628